Effect of Oral and Intravenous Diltiazem on Whole Blood Platelet Aggregability

References

• Prentice C. RM. Myocardial infarction. Thrombosis: Clinics in Haematology 1981; 10: 521–541
   Google Scholar
• Born G. VR. Platelets in atherogenesis and thrombogenesis. Biology and Pathology of the Vessel Wall, N. Woolf. Praeger Scientific, Eastbourne 1983; 71–80
   Google Scholar
• Ikeda Y., Kikuchi M., Toyama K., Watanabe K., Ando Y. Inhibition of human platelet function by verapamil. Thromb Haemost. 1981; 45: 158–161
   Google Scholar
• Shinjo A., Sasaki Y., Inamasu M., Morita T. In vitro effect of the coronary vasodilator diltiazem on human and rabbit platelets. Thromb Res. 1978; 13: 941–955
   Google Scholar
• Mehta P., Mehta J., Ostrowski N., Brigmon L. Inhibitory effects of diltiazem on platelet activation caused by ionophore A23187 plus ADP or epinephrine in subthreshold concentrations. J Lab Clin Med. 1983; 102: 332–339
   Google Scholar
• Kiyomoto A., Sasaki Y., Odawara A., Morita T. Inhibition of platelet aggregation by diltiazem. Circ Rex 1983; 52(suppl 1)115–119
   Google Scholar
• Altman R., Scazziota A., Dujovne C. Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation. Clin Pharmacol Ther. 1988; 44: 320–325
   Google Scholar
• Schachter M. Do calcium antagonists affect platelets?. Eur Heart J. 1987; 8: 75–82
   Google Scholar
• Strano A., Davi G., Novo S., Custro N., Mattina A., Gallo V. Effects of verapamil on platelet aggregation and serum thromboxane synthesis in vitro and in vivo. Inter Angio. 1985; 4: 379–382
   Google Scholar
• Ring M., Corrigan J., Fenster P. Effects of oral diltiazem on platelet function: alone and in combination with low dose aspirin. Thromb Res. 1986; 44: 391–400
   Google Scholar
• Yamauchi K., Furui H., Taniguchi N., Sotobata I. Effects of diltiazem hydrochloride on cardiovascular response, platelet aggregation and coagulating activity during exercise testing in systemic hypertension. Am J Cardiol. 1986; 57: 609–612
   Google Scholar
• Cremer K., Pieper J., Joyal M., Mehta J. Effects of diltiazem, dipyridamole, and their combination on hemostasis. Clin Pharmacol Ther. 1984; 36: 641–644
   Google Scholar
• Johnson H. Effects by nifedipine on platelet function in vitro and in vivo. Thromb Rex 1981; 21: 523–528
   PubMed Web of Science ®Google Scholar
• Dale J., Landmark K., Myhre E. The effects of nifedipine, a calcium antagonist, on platelet function. AmHeartJ. 1983; 105: 103–105
   Google Scholar
• Hiroki T., Inoue T., Yoshida T., Arakawa K. Effect of calcium antagonistic agent nifedipine on platelet aggregation response to exercise in patients with angina pectoris. Arzneim Forsch. 1982; 32: 1572–1574
   Google Scholar
• Sebekova K., Raucinova M., Sedlakova K., Dzurik R. Serotonin metabolism and platelet aggregation under antihypertensive treatment with nitrendipine. J Cardiovasc Pharmacol. 1988; 12(Suppl 4)S161–S163
   Google Scholar
• Francis J. L., Roath O. S., Challenor V. T., Waller D. G. The effect of nisodipine on whole blood platelet aggregation in patients with Raynaud's phenomenon. Br J Pharmac. 1988; 25: 751–754
   Google Scholar
• Ring M. E., Martin G. V., Fenster P. E. Clinically significant antiplatelet effects of calcium-channel blockers. J Clin Pharmacol. 1986; 26: 719–720
   Google Scholar
• Rostagno C., Prisco D., Paniccia R., Costanzo G., Poggesi L., Boddi M. Effects of calcium channel blockers on platelet aggregation and thromboxane A2 formation: an in vivo double blind randomized study. Thromb Res. 1990; 59: 531–539
   Google Scholar
• Hermann P. H., Rodger S. D., Remones G., Thenot J. P., London D. R., Morselli P. L. Pharmacokinetics of diltiazem after intravenous and oral administration. Eur J Pharmacol. 1983; 24: 349–352
   Google Scholar
• Smith M., Verghese C. P., Shand D. G., Pritchett E. LC. Pharmacokinetic and pharmacodynamic effects of diltiazem. Am J Cardiol. 1983; 51: 1369–1374
   PubMed Web of Science ®Google Scholar
• Mitchell L. B., Jutzy K. R., Lewis S. J., Schroeder I. S., Mason J. W. Intracardiac electrophysiologic study of intravenous diltiazem and combined diltiazem-digoxin in patients. Am Heart J. 1982; 103: 57–65
   PubMed Web of Science ®Google Scholar
• Ingerman-Wojenski C. M., Silver M. I. A quick method for screening platelet dysfunctions using the whole blood lumi-aggregometer. Thromb Haemost. 1984; 51: 154–156
   PubMed Web of Science ®Google Scholar
• Zhao H., Chow M. SS. Analysis of diltiazem and desacetyldiltiazem in plasma using modified high-performance liquid chromatography: improved sensitivity and reproducibility. Pharmaceutical Research 1989; 6: 428–430
   PubMedGoogle Scholar
• Riess H., Braun G., Brehm G., Hiller E. Critical evaluation of platelet aggregation in whole human blood. Am J Clin Pathol. 1986; 85: 50–56
   PubMed Web of Science ®Google Scholar
• Jeremy J. Y., Barradas M. A., Mikhailidis D. P., Dandona P. An investigation into the effects of nifedipine and nimodipine on platelet function and vascular prostacyclin synthesis. Drugs Exptl Clin Res. 1985; 11: 645–651
   Google Scholar
• Tartaglione T., Pepine C., Pieper J. Diltiazem: a review of its clinical efficacy and use. Drug Intelligence and Clinical Pharmacy 1982; 16: 371–379
   Google Scholar
• Kinney E. L., Moskowitz R. M., Zelis R. The pharmacokinetics and pharmacology of oral diltiazem in normal volunteers. J Clin Pharmacol. 1981; 21: 337–342
   Google Scholar
• Zelis R. F. Calcium entry blockers in cardiologic therapy. Hosp Pract. 1981; 16: 52
   Google Scholar
• Onoda J. M., Sloane B. F., Honn K. F. Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors. Thromb Res. 1984; 34: 367–378
   Google Scholar
• Greer I. A., Walker J. J., Calder A. A., Forbes C. D. Aspirin with an adrenergic or a calcium-channel blocking agent as a new combination therapy for arterial thrombosis. Lancet 1985; 1: 351–352
   Google Scholar